<DOC>
	<DOCNO>NCT02574754</DOCNO>
	<brief_summary>The purpose study ass 2012 bioequivalence statistical criterion warfarin , narrow therapeutic index drug , set forth draft guidance issue Food Drug Administration ( FDA ) .</brief_summary>
	<brief_title>Assessment 2012 Bioequivalence Standards Warfarin</brief_title>
	<detailed_description>This study reasonable start point ass appropriateness 2012 FDA bioequivalence ( BE ) statistical criterion narrow therapeutic index drug ( NTIDs ) . The idea stem early study conduct Dr. Benet 's lab drug furosemide . The furosemide study yield triplicate data unable purely meet BE statistical criterion set forth FDA due inherent study design . Furosemide NTID consider FDA BE study , however . Hence , investigator propose new study ass BE statistical criterion warfarin , NTID draft guidance issue FDA . By provide reference product ( brand name warfarin ) three time study participant record relevant pharmacokinetic parameter BE ( AUC Cmax ) , investigator make three comparison data ( R1 R2 vs. R2 R3 ; R1 R2 vs. R1 RÂ¬3 ; R2 R3 vs. R1 R3 ) . The investigator three concern test . 1 . Will normal within subject variability potentially lead inequivalence reference product use new NTID BE regulation ? 2 . Is possible BE interval could less United States Pharmacopeia ( USP ) content uniformity limit warfarin ? 3 . Provide comparison within-subject variance 2.5 ratio comparison .</detailed_description>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Male female age 1860 year Healthy adult without active medical problem chronic disease base medical history , physical exam , laboratory result BMI 18.532 kg/m2 Ceased medication 2 week prior start study study enrollment ( include drug abuse , prescription medication , overthecounter ( OTC ) medication [ exception : acetaminophen ] ) Maintain adequate birth control independent hormonal contraceptive use throughout study Provide write informed consent take part comply requirement study Speak , read , understand English Avoid alcohol , caffeine , orange juice 6pm night study day completion study day Avoid contact sport and/or activity significant risk trauma injury 7 day study day Do eat food consume beverage least 8 hour medication dose Present wild type VKORC1 , VKORC1639G &gt; A wild type CYP2C9 genotype Subjects prescription chronic OTC medication ( include hormonal contraceptive ) Subjects know allergy warfarin Subjects history diagnosis hemorrhagic tendency blood dyscrasias Subjects liver failure liver function test ( LFTs ) &gt; 2x upper limit normal Subjects clinically significant elevation international normalized ratio ( INR ) , prothrombin time ( PT ) , partial thromboplastin time ( PTT ) , serum creatinine ( Scr ) , blood urea nitrogen ( BUN ) , screen laboratory test determine study physician Subjects hematocrit ( Hct ) &lt; 30 mg/dL Subjects history GI bleed peptic ulcer disease Subjects recent history trauma Subjects recent history upcoming plan surgery Subjects smoke tobacco Subjects ongoing alcohol use Subjects ongoing illegal drug use Subjects pregnant , attempt become pregnant , lactating Subjects unable maintain adequate birth control study Subjects unable follow protocol instruction criteria Subjects genotypes wild type VKORC1 , VKORC1639G &gt; A wild type CYP2C9</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>warfarin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>